市场调查报告书

小鼠模型的全球市场

Mice Model

出版商 Global Industry Analysts, Inc. 商品编码 956871
出版日期 内容资讯 英文 397 Pages
商品交期: 最快1-2个工作天内
价格
小鼠模型的全球市场 Mice Model
出版日期: 2020年09月01日内容资讯: 英文 397 Pages
简介

全球小鼠模型的市场规模在2020年~2027年的期间中预计将以6.3%的年复合成长率增长,从2020年的13亿美元达到2027年20亿美元的规模。市场区隔之一的CRISPR/CAS9在分析期间结束前预测将以7.3%的年率增长,并达到6亿9,730万美元的规模。

本报告提供全球小鼠模型市场的相关调查,提供市场占有率,趋势和预测,成长要素,各地区的市场分析,竞争情形,主要企业的简介等资讯。

调查对象企业范例

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings (LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

目录

I. 简介,调查手法 、 调查范围

II. 摘要整理

  • 市场概要
    • Covid-19的影响和即将到来的全球景气衰退
    • 竞争的市场占有率
    • 竞争的市场占有率方案
  • 主要企业
  • 趋势与成长要素
  • 全球市场预测

III. 市场分析

  • 各地区市场分析
  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美国家
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他中东
  • 非洲

IV. 竞争

  • 企业简介:43公司
目录
Product Code: MCP13287

Global Mice Model Market to Reach $2 Billion by 2027

Amid the COVID-19 crisis, the global market for Mice Model estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 6.3% over the analysis period 2020-2027. CRISPR/CAS9, one of the segments analyzed in the report, is projected to record a 7.3% CAGR and reach US$697.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Microinjection segment is readjusted to a revised 5.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $351.4 Million, While China is Forecast to Grow at 9.7% CAGR

The Mice Model market in the U.S. is estimated at US$351.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$432.5 Million by the year 2027 trailing a CAGR of 9.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

Embryonic Stem Cell Injection Segment to Record 5.9% CAGR

In the global Embryonic Stem Cell Injection segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$184.5 Million in the year 2020 will reach a projected size of US$266.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$269.6 Million by the year 2027, while Latin America will expand at a 7.1% CAGR through the analysis period. We bring years of research experience to this 8th edition of our report. The 397-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings (LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • Global Competitor Market Shares
    • Mice Model Competitor Market Share Scenario Worldwide (in %): 2018E
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 2: World Historic Review for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 3: World 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for CRISPR/CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 5: World Historic Review for CRISPR/CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 6: World 15-Year Perspective for CRISPR/CAS9 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 8: World Historic Review for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 9: World 15-Year Perspective for Microinjection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 11: World Historic Review for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 12: World 15-Year Perspective for Embryonic Stem Cell Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 14: World Historic Review for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 15: World 15-Year Perspective for Nuclear Transfer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 17: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 18: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 20: World Historic Review for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 21: World 15-Year Perspective for Breeding by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 23: World Historic Review for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 24: World 15-Year Perspective for Cryopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 26: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 27: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 29: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 30: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Oncology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 32: World Historic Review for Oncology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 33: World 15-Year Perspective for Oncology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Immunology & Inflammation Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 35: World Historic Review for Immunology & Inflammation Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 36: World 15-Year Perspective for Immunology & Inflammation Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Diabetes Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 38: World Historic Review for Diabetes Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 39: World 15-Year Perspective for Diabetes Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Cardiovascular Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 41: World Historic Review for Cardiovascular Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 42: World 15-Year Perspective for Cardiovascular Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Central Nervous System (CNS) Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 44: World Historic Review for Central Nervous System (CNS) Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 45: World 15-Year Perspective for Central Nervous System (CNS) Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 46: World Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 47: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 48: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Mice Model Market Share (in %) by Company: 2018 &
    • Market Analytics
    • TABLE 49: USA Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 50: USA Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 51: USA 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 52: USA Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 53: USA Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 54: USA 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 55: USA Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 56: USA Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 57: USA 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 58: Canada Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 59: Canada Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 60: Canada 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 61: Canada Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 62: Canada Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 63: Canada 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 64: Canada Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 65: Canada Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 66: Canada 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 67: Japan Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 68: Japan Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 69: Japan 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 70: Japan Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 71: Japan Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 72: Japan 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 73: Japan Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 74: Japan Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 75: Japan 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 76: China Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 77: China Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 78: China 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 79: China Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 80: China Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 81: China 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 82: China Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 83: China Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 84: China 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • EUROPE
    • Market Facts & Figures
    • European Mice Model Market: Competitor Market Share Scenario (in %) for 2018 &
    • Market Analytics
    • TABLE 85: Europe Current & Future Analysis for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 86: Europe Historic Review for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 87: Europe 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 88: Europe Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 89: Europe Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 90: Europe 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 91: Europe Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 92: Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 93: Europe 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 94: Europe Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 95: Europe Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 96: Europe 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 97: France Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 98: France Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 99: France 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 100: France Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 101: France Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 102: France 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 103: France Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 104: France Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 105: France 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 106: Germany Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 107: Germany Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 108: Germany 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 109: Germany Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 110: Germany Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 111: Germany 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 112: Germany Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 113: Germany Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 114: Germany 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 115: Italy Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 116: Italy Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 117: Italy 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 118: Italy Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 119: Italy Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 120: Italy 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 121: Italy Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 122: Italy Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 123: Italy 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 124: UK Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 125: UK Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 126: UK 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 127: UK Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 128: UK Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 129: UK 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 130: UK Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 131: UK Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 132: UK 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 133: Spain Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 134: Spain Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 135: Spain 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 136: Spain Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 137: Spain Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 138: Spain 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 139: Spain Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 140: Spain Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 141: Spain 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 142: Russia Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 143: Russia Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 144: Russia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 145: Russia Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 146: Russia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 147: Russia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 148: Russia Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 149: Russia Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 150: Russia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 151: Rest of Europe Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 152: Rest of Europe Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 153: Rest of Europe 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 154: Rest of Europe Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 155: Rest of Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 156: Rest of Europe 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of Europe Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 158: Rest of Europe Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 159: Rest of Europe 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 160: Asia-Pacific Current & Future Analysis for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 161: Asia-Pacific Historic Review for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 162: Asia-Pacific 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 163: Asia-Pacific Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 164: Asia-Pacific Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 165: Asia-Pacific 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 166: Asia-Pacific Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 167: Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 168: Asia-Pacific 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 169: Asia-Pacific Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 170: Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 171: Asia-Pacific 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 172: Australia Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 173: Australia Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 174: Australia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 175: Australia Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 176: Australia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 177: Australia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 178: Australia Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 179: Australia Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 180: Australia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 181: India Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 182: India Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 183: India 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 184: India Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 185: India Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 186: India 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 187: India Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 188: India Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 189: India 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 190: South Korea Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 191: South Korea Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 192: South Korea 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 193: South Korea Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 194: South Korea Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 195: South Korea 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 196: South Korea Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 197: South Korea Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 198: South Korea 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 199: Rest of Asia-Pacific Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 200: Rest of Asia-Pacific Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 201: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 202: Rest of Asia-Pacific Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 203: Rest of Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 204: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 205: Rest of Asia-Pacific Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 206: Rest of Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 207: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 208: Latin America Current & Future Analysis for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 209: Latin America Historic Review for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 210: Latin America 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 211: Latin America Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 212: Latin America Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 213: Latin America 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 214: Latin America Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 215: Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 216: Latin America 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 217: Latin America Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 218: Latin America Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 219: Latin America 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 220: Argentina Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 221: Argentina Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 222: Argentina 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 223: Argentina Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 224: Argentina Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 225: Argentina 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 226: Argentina Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 227: Argentina Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 228: Argentina 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 229: Brazil Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 230: Brazil Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 231: Brazil 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 232: Brazil Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 233: Brazil Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 234: Brazil 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 235: Brazil Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 236: Brazil Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 237: Brazil 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 238: Mexico Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 239: Mexico Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 240: Mexico 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 241: Mexico Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 242: Mexico Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 243: Mexico 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 244: Mexico Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 245: Mexico Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 246: Mexico 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 247: Rest of Latin America Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 248: Rest of Latin America Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 249: Rest of Latin America 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 250: Rest of Latin America Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 251: Rest of Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 252: Rest of Latin America 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 253: Rest of Latin America Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 254: Rest of Latin America Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 255: Rest of Latin America 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 256: Middle East Current & Future Analysis for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through
    • TABLE 257: Middle East Historic Review for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 258: Middle East 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 259: Middle East Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 260: Middle East Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 261: Middle East 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 262: Middle East Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 263: Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 264: Middle East 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 265: Middle East Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 266: Middle East Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 267: Middle East 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 268: Iran Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 269: Iran Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 270: Iran 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 271: Iran Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 272: Iran Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 273: Iran 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 274: Iran Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 275: Iran Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 276: Iran 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 277: Israel Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 278: Israel Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 279: Israel 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 280: Israel Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 281: Israel Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 282: Israel 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 283: Israel Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 284: Israel Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 285: Israel 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 286: Saudi Arabia Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 287: Saudi Arabia Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 288: Saudi Arabia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 289: Saudi Arabia Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 290: Saudi Arabia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 291: Saudi Arabia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 292: Saudi Arabia Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 293: Saudi Arabia Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 294: Saudi Arabia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 295: UAE Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 296: UAE Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 297: UAE 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 298: UAE Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 299: UAE Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 300: UAE 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 301: UAE Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 302: UAE Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 303: UAE 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 304: Rest of Middle East Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 305: Rest of Middle East Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 306: Rest of Middle East 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 307: Rest of Middle East Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 308: Rest of Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 309: Rest of Middle East 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 310: Rest of Middle East Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 311: Rest of Middle East Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 312: Rest of Middle East 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 313: Africa Current & Future Analysis for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 314: Africa Historic Review for Mice Model by Technology - CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 315: Africa 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 316: Africa Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 317: Africa Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 318: Africa 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing and Other Services for the Years 2012, 2020 & 2027
    • TABLE 319: Africa Current & Future Analysis for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through
    • TABLE 320: Africa Historic Review for Mice Model by Therapeutic Area - Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through
    • TABLE 321: Africa 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Studies, Immunology & Inflammation Studies, Diabetes Studies, Cardiovascular Studies, Central Nervous System (CNS) Studies and Other Therapeutic Areas for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43